Difference between revisions of "Team:ETH Zurich"

(Partially port page to new style; remove elements absent in HTML5; reorganize.)
Line 1: Line 1:
−
{{ETH_Zurich_2}}
+
{{ETH_Zurich/Head_N_Prefix}}
−
 
+
 
<html>
 
<html>
−
 
+
<link rel="stylesheet" type="text/css" href="/Template:ETH_Zurich/safety_css?action=raw&ctype=text/css">
 +
</html>
 +
{{ETH_Zurich/Head_N_Suffix}}
 +
{{ETH_Zurich/Header_N}}
 +
<html>
 +
<main role="main">
 
<head>
 
<head>
−
<meta charset="utf-8">
 
−
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=yes">
 
−
 
−
<script>
 
−
    $(function() {
 
−
    $('a[href*=#]').on('click', function(e) {
 
−
    e.preventDefault();
 
−
    $('html, body').animate({ scrollTop: $($(this).attr('href')).offset().top}, 500, 'linear');
 
−
    });
 
−
    });
 
−
</script>
 
−
 
−
 
 
<style>
 
<style>
−
 
−
 
 
body {
 
body {
 
     font-family: 'Avenir', 'Open Sans', 'HelveticaNeue', 'Helvetica Neue', Helvetica, Arial, sans-serif!important;
 
     font-family: 'Avenir', 'Open Sans', 'HelveticaNeue', 'Helvetica Neue', Helvetica, Arial, sans-serif!important;
 
}
 
}
−
 
  
 
div.title {
 
div.title {
 
     padding: 100px;
 
     padding: 100px;
 
}
 
}
−
 
  
 
div.content {
 
div.content {
Line 39: Line 26:
 
     line-height: 130%;  
 
     line-height: 130%;  
 
}
 
}
−
 
  
 
img.AND {
 
img.AND {
−
  padding-top: 50px;
+
    padding-top: 50px;
−
  padding-bottom: 50px;
+
    padding-bottom: 50px;
 
}
 
}
  
Line 55: Line 41:
 
     padding-right: 80px;
 
     padding-right: 80px;
 
}
 
}
−
 
  
 
a.more {
 
a.more {
Line 64: Line 49:
 
     font-weight: 900;
 
     font-weight: 900;
 
}
 
}
−
 
−
 
 
</style>
 
</style>
−
 
 
</head>
 
</head>
−
 
+
<div class="title" style="margin:auto">  
−
 
+
    <a href="https://2017.igem.org/Team:ETH_Zurich">
−
<body>
+
        <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" width="900px"/>
−
 
+
    </a>
−
<div class="title">  
+
−
  <center>
+
−
      <a href="https://2017.igem.org/Team:ETH_Zurich">
+
−
      <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" width="900px">
+
−
      </a>
+
−
  <center>
+
 
</div>
 
</div>
  
−
 
+
<div style="margin:auto;">  
−
<center>  
+
 
     <a href="#start">
 
     <a href="#start">
−
    <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png" width="70px">
+
        <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png" width="70px">
 
     </a>
 
     </a>
−
</center>
+
</div>
−
 
+
  
 
<div class="content">  
 
<div class="content">  
−
  <div id="start">
+
    <div id="start">
−
      Cancer kills over 8 million people every year. That's the entire population of Switzerland! <br><br>
+
        <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
 +
        <p>We need more specific therapies because current approaches result in many side-effects.</p>
 +
        <p>That's why we created CATE: Cancer-Targeting E. coli.</p>
 +
        <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a>
 +
        <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" width="500px" align="right">
 +
    </div>
  
−
      We need more specific therapies because current approaches result in many side-effects.<br>
+
    <div id="second">
−
      That's why we created CATE: Cancer-Targeting E. coli.
+
        <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="400px" align="left">
−
      <br>
+
        <p>CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
−
      <br>
+
        <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a>
+
    </div>
−
      <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" width="500px" align="right">
+
−
  </div>
+
  
−
  <div id="second">
+
    <div id="third">
−
      <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="400px" align="left">
+
        <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p>
−
 
+
        <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND" width="730px">
−
      CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI
+
        <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p>
−
      contrast and a cytotoxic agent so it can deliver both components to tumor sites.
+
        <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a>
−
      <br>
+
−
      <br>
+
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
+
 
     </div>
 
     </div>
−
 
−
  <div id="third">
 
−
      CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
 
−
      <center>
 
−
        <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND" width="730px">
 
−
      </center>
 
−
 
−
      <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p>
 
−
      <br>
 
−
      <br>
 
−
      <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a>
 
−
  </div>
 
−
 
−
 
−
 
−
 
 
</div>
 
</div>
−
 
+
</main>
−
 
+
<script>
−
</body>
+
$(function() {
 +
        $('a[href*=#]').on('click', function(e) {
 +
            e.preventDefault();
 +
            $('html, body').animate({ scrollTop: $($(this).attr('href')).offset().top}, 500, 'linear');
 +
            });
 +
        });
 +
</script>
 
</html>
 
</html>
−
 
+
{{ETH_Zurich/Footer_N}}
−
 
+
−
 
+
−
<!--{{ETH_Zurich/footer2}}-->
+
−
 
+
−
 
+
−
{{ETH_Zurich/mainJS}}
+
−
{{ETH_Zurich/jquery2JS}}
+
−
<!--{{ETH Zurich/jqueryJS}}-->
+
−
{{ETH_Zurich/BootstrapMinJS}}
+

Revision as of 04:10, 15 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.

That's why we created CATE: Cancer-Targeting E. coli.

Learn more

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design